Predictive Oncology Inc.
POAI
$0.832
$0.0020.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,151.02% | 91.36% | -48.91% | -43.13% | -97.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,151.02% | 91.36% | -48.91% | -43.13% | -97.96% |
| Cost of Revenue | 101.34% | 20.18% | 101.12% | -4.26% | -81.35% |
| Gross Profit | 470.45% | 312.60% | -74.29% | -61.91% | -114.69% |
| SG&A Expenses | -34.01% | -21.15% | -25.77% | -19.67% | -0.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.16% | -18.16% | -22.13% | -19.09% | -3.18% |
| Operating Income | 36.15% | 29.74% | 15.52% | 15.99% | -3.38% |
| Income Before Tax | 35.88% | 29.79% | 16.92% | 18.91% | -4.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.88% | 29.79% | 16.92% | 18.91% | -4.16% |
| Earnings from Discontinued Operations | 75.94% | 85.78% | -95.45% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.09% | 37.57% | 2.17% | 18.91% | -23.29% |
| EBIT | 36.15% | 29.74% | 15.52% | 15.99% | -3.38% |
| EBITDA | 36.46% | 30.19% | 11.75% | 16.35% | -9.95% |
| EPS Basic | 67.10% | 62.01% | 38.35% | 30.53% | -20.42% |
| Normalized Basic EPS | 63.58% | 58.13% | 46.46% | 27.53% | -1.73% |
| EPS Diluted | 67.15% | 62.01% | 38.35% | 30.53% | -20.75% |
| Normalized Diluted EPS | 63.58% | 58.13% | 46.46% | 27.53% | -1.73% |
| Average Basic Shares Outstanding | 76.04% | 64.32% | 58.66% | 16.72% | 2.39% |
| Average Diluted Shares Outstanding | 76.04% | 64.32% | 58.66% | 16.72% | 2.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |